Argos Therapeutics (ARGS) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Argos Therapeutics Reports Second Quarter 2015 Financial Results and Operational Highlights
August 12, 2015 4:05 PM EDT- Independent Data Monitoring Committee (IDMC) Recommended Continuation of Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 -
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 -
- Established Scientific Advisory Board -
- Conference Call and Webcast Today, August 12th, at 4:30 p.m. ET -
DURHAM, N.C., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the... More
